

#3
63 c'd PCT/PTO 27 NOV 1998

09/101413

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans Josef Stauss

Serial No.: 09/101,413 NOV 23 1998 Art Unit: Not Yet Assigned

Filed: July 10, 1998 Examiner: Not Yet Assigned

For: *Immunotherapy Using Cytotoxic T Lymphocytes (CTL)*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97,
applicant submits an Information Disclosure Statement, including six (6) pages of Form 1449
and copies of the documents cited therein. The document marked by an asterisk (*) will be
filed in a Supplemental Information Disclosure Statement.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to
a first Office Action on the merits. It is believed that no fee is required with this submission.
However, should a fee be required, the Commissioner is hereby authorized to charge any fees
to Deposit Account No. 01-2507. To facilitate this process, Applicant encloses a duplicate of
this document.

United States Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
US 5,081,029	1/14/92	Zarling, et al.	435/172.3
US 5,359,046	10/25/94	Capon, et al.	536/23.4

Foreign Patents and Applications

<u>Number</u>	<u>Publication Date</u>	<u>Country/Region</u>
WO 91/04317	4/4/91	PCT
WO 9201459	2/6/92	PCT
WO 92/05794	4/16/92	PCT
WO 93/17095	9/2/93	PCT
WO 94/21287	9/29/94	PCT
WO 95/04817	2/16/95	PCT
WO 95/18969	7/13/95	PCT
WO 95/22561	8/24/95	PCT
EP-257962	2/3/88	EP
EP-360205	3/28/90	EP
EP-415666	6/3/91	EP
EP-523948	1/20/93	EP
J61176529	8/8/86	Japan

Publications

- Alexander, et al., "Differential Transport Requirements of HLA and H-2 Class I Glycoproteins," *Immunogenetics* 29:380-388 (1989).
- Bakker, et al., "Melanocyte Lineage-Specific Antigen gp100 is Recognized by Melanoma-Derived Tumor-Infiltrating Lymphocytes," *J. Exp. Med.* 179:1005-1009 (1994).
- Boël, et al., "BAGE: a New Code Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes," *Immunity* 2(2):167-175 issn. 1074-7613 (1995).
- Chung, et al., "Functional Three-Domain Single-Chain T-Cell Receptors," *Proc. Natl. Acad. Sci. USA* 91:12654-12658 (1994).
- Cox, et al., "Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines," *Science* 264:716-719 (1994).
- Eshhar, et al., "Specific Activation and Targeting of Cytotoxic Lymphocytes Through Chimeric Single Chains Consisting of Antibody-Binding Domains and the (or . Subunits of the Immunoglobulin and T-Cell Receptors," *Proc. Natl. Acad. Sci. USA* 90(N2): 720-724 (1993).
- Faber, et al., "Generation of Leukemia-reactive Cytotoxic T Lymphocyte Clones from the HLA-identical Bone Marrow Donor of a Patient with Leukemia," *J. Exp. Med.* 176(5):1283-1289 (1992).
- Falkenberg, et al., "Generation of Donor-Derived Antileukemic Cytotoxic T-Lymphocyte Responses for Treatment of Relapsed Leukemia After Allogeneic HLA-Identical Bone Marrow Transplantation," *J. Immunotherapy* 14(4):305-309 issn. 1053-8550 (1993).

Fidler & Nicholson, "Brief Communication: Organ Selectivity for Implantation

Survival and Growth of B16 Melanoma Variant Tumor Lines," *J. Natl. Cancer Inst.* 57:1199-1202 (1976).

Finer, et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," *Blood* 83:43-50 (1994).

Gagliardi, et al., "Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes *in vitro*," *Intl. Immunol.*, 7(11):1741-1752 (1995).

Goldman, "Allogenic Bone Marrow Transplantation: State of the Art and Future Directions," *Bone Marrow Transplant* 1:133-134 (1989).

Heath, et al., "Peptide-dependent recognition of H-2K^b by alloreactive cytotoxic T lymphocytes," *Nature*, 341(6244):749-752 (1989).

Hwu, et al., "Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected with a Chimeric Gene Composed of an Antibody Variable Region and the Fc Receptor (Chain)," *J. Exp. Med.* 178:361-366 (1993).

Kast, et al., "Eradication of Adenovirus E1-Induced Tumors by E1A-Specific Cytotoxic T Lymphocytes," *Cell* 59(4):603-614 (1989).

Kawakami, et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with *in vivo* tumor rejection," *Proc. Natl. Acad. Sci. USA* 91(14):6458-6462 (1994).

Kawakami, et al., "Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor," *Proc. Natl. Acad. Sci. USA* 91(9):3515-3519 (1994).

Kawakami, et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-Restricted Tumor Infiltrating Lymphocytes," *J. Exp. Med.* 180:347-352 (1994).

Ljunggren & Kärre, "Host Resistance Directed Selectively Against H-2-Deficient Lymphoma Variants," *J. Exp. Med.* 162:1745-1759 (1985).

Moritz, et al., "Cytotoxic T Lymphocytes with a Grafted Recognition Specificity for ERBB2-Expressing Tumor Cells," *Proc. Natl. Acad. Sci. USA* 91:4318-4322 (1994).

Nixon & McMichael, "Cytotoxic T-Cell Recognition of HIV Proteins and Peptides," *AIDS* 5(9):1049-1059 (1991).

Nowak, et al., "Antigenic Oscillations and Shifting Immunodominance in HIV-1 Infections," *Nature* 375(6532):606-611 (1995).

Riddell, et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," *Science* 257(5067):238-241 (1992).

Roberts, et al., "Targeting of Human Immunodeficiency Virus-Infected Cells by CD8+ T Lymphocytes Armed with Universal T-Cell Receptors," *Blood* 84:2878-2889 (1994).

Rojo, et al., "Peptide-Mediated Allo-Recognition of HLA-B27 by Cytotoxic T Lymphocytes," *Int. J. Cancer: Suppl.* 6:10-13 (1991).

Stauss and Dahl, "Cellular Oncogenes for Tumour Immunity: Immunotherapy,"

Tumour Immunology, Dalgleish/Browning, Chapter 7 (1995).

Theobald, et al., "Targeting p53 as a General Tumor Antigen," *Proc. Natl. Acad. Sci. USA* 92:11993-11997 (1995).

Torpey , et al., "Effects of Adoptive Immunotherapy with Autologous CD8+ T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity," *Clin. Immunol. Immunopathol.* 68(3):263-272 (1993).

Traversari, et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E," *J. Exp. Med.* 176:1453-1457 (1992).

van der Bruggen, et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," *Science* 254:1643-1647 (1991).

van Lochem, et al., "*In vitro* separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities," *Bone-Marrow-Transplantation* 10(2):181-183 (1992).

Walker & Plata, "Editorial Review: Cytotoxic T Lymphocytes Against HIV," *AIDS* 4(3):177-184 (1990).

Wölfel, et al., "Two Tyrosinase Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes," *Eur. J. Immunol.* 24:759-764 (1994).

*Yang, et al., "Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules" *J. Biol. Chem.* 267:11669-11672 (1992).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, applicant invites the Examiner to make an independent evaluation of the cited art to determine its materiality and relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the prior art referred to herein, either alone or in combination.

Respectfully submitted,



Patrell L. Pabst
Reg. No. 31,284


Date: November 20, 1998

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

Certificate of Mailing under 37 CFR § 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: November 20, 1998


Kristin Herring